146 related articles for article (PubMed ID: 9923547)
21. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel.
Aebi S; Schnider TW; Los G; Heath DD; Darrah D; Kirmani S; McClay EF; D'Agostino H; Plaxe SC; Fink D; De las Alas MM; Howell SB; Christen RD
Cancer Chemother Pharmacol; 1999; 44(3):259-65. PubMed ID: 10453729
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
van Zuylen L; Karlsson MO; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Cancer Chemother Pharmacol; 2001 Apr; 47(4):309-18. PubMed ID: 11345647
[TBL] [Abstract][Full Text] [Related]
23. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
Gauvin A; Pinguet F; Culine S; Astre C; Gomeni R; Bressolle F
Clin Cancer Res; 2000 Jul; 6(7):2690-5. PubMed ID: 10914711
[TBL] [Abstract][Full Text] [Related]
24. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
[TBL] [Abstract][Full Text] [Related]
25. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
26. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
27. Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Juan O; Rocher A; Sánchez A; Sánchez JJ; Alberola V
Chemotherapy; 2005 Jul; 51(4):200-5. PubMed ID: 15985759
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Ibrahim NK; Desai N; Legha S; Soon-Shiong P; Theriault RL; Rivera E; Esmaeli B; Ring SE; Bedikian A; Hortobagyi GN; Ellerhorst JA
Clin Cancer Res; 2002 May; 8(5):1038-44. PubMed ID: 12006516
[TBL] [Abstract][Full Text] [Related]
29. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
[TBL] [Abstract][Full Text] [Related]
30. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Mielke S; Sparreboom A; Steinberg SM; Gelderblom H; Unger C; Behringer D; Mross K
Clin Cancer Res; 2005 Jul; 11(13):4843-50. PubMed ID: 16000582
[TBL] [Abstract][Full Text] [Related]
31. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
32. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of paclitaxel-containing liposomes in rats.
Fetterly GJ; Straubinger RM
AAPS PharmSci; 2003 Nov; 5(4):E32. PubMed ID: 15198520
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the linearity of docetaxel pharmacokinetics.
McLeod HL; Kearns CM; Kuhn JG; Bruno R
Cancer Chemother Pharmacol; 1998; 42(2):155-9. PubMed ID: 9654116
[TBL] [Abstract][Full Text] [Related]
38. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Panday VR; ten Bokkel Huinink WW; Vermorken JB; Rosing H; Koopman FJ; Swart M; Schellens JH; Beijnen JH
Pharmacol Res; 1999 Jul; 40(1):67-74. PubMed ID: 10378993
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers.
Dias ML; Carvalho JP; Rodrigues DG; Graziani SR; Maranhão RC
Cancer Chemother Pharmacol; 2007 Jan; 59(1):105-11. PubMed ID: 16699792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]